SCHEMBL1509518

SCHEMBL1509518

O=C(O)c1ccc2[nH]c(-c3cc(-c4cccnc4O)ccc3O)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ RAB9A P51151 4/20 0.42
▸ NPC1 O15118 3/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ POLB P06746 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ FHIT P49789 1/20 0.41
▸ NR4A2 P43354 1/20 0.41
▸ MMP2 P08253 1/20 0.41
▸ MMP9 P14780 1/20 0.41
▸ MMP8 P22894 1/20 0.41
▸ MMP13 P45452 1/20 0.41
▸ CHEK2 O96017 2/20 0.41
▸ ADORA2A P29274 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16462113 0.92 NR4A2 (0.52) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL4702856 0.87 DHODH (0.46) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL12471073 0.80 F2 (0.55) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL31429585 0.80 F2 (0.55) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL4814403 0.80 NR4A2 (0.59) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL14090378 0.80 MMP2 (0.50) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL1509482 0.79 CHEK2 (0.53) KMT2ARAB9ANPC1POLBTP53
SCHEMBL12834513 0.78 LOXL2 (0.47) CHEK2HDAC6HDAC3HDAC1HDAC2
SCHEMBL1761767 0.77 KDM4E (0.45) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL14090183 0.77 CHEK2 (0.58) KDM4EKMT2AALDH1A1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629147-B2 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION (US) 2014-01-14 — — US disclosed
EP-2298770-A1 Heterocyclic compounds as TrkA modulators ChemBridge Corporation (US) 2011-03-23 — — EP disclosed
EP-1960382-A1 HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS ChemBridge Research Laboratories, Inc. (US) 2008-08-27 — — EP disclosed
WO-2007056155-A1 HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) 2007-05-18 — — WO disclosed
Send feedback